Science Daily

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
MedPage Today

Triple Therapy in Metastatic CRC With BRAF Mutations: The New Standard of Care?

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...
ascopubs.org

Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
CURE

FDA Approves Guardant360 CDx Diagnostic For Some With Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
EurekAlert!

A new study explores why the same mutation in the BRAF gene leads to different therapeutic responses to its inhibitors in melanoma and colorectal cancer

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
ascopubs.org

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.

Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor. Outcomes of ...
Reuters

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
News Medical

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
News Medical

Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
MedPage Today on MSN

Targeted duo wins again in BRAF-mutant colorectal cancer

Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...
Seeking Alpha

Pfizer gets FDA accelerated approval for Braftovi

Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF gene ...